RegeneRx Biopharmaceuticals Inc (PK:RGRX)

Aug 01, 2023 12:34 pm ET
RegeneRx To Extend Consent Solicitation Vote
ROCKVILLE, Md., Aug. 1, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair, and regeneration, announced that, pursuant to the company's consent solicitation dated July 11, 2023, holders of 48.5% of the Company's outstanding stock have voted to date, with 94% voting in favor of the proposed reverse stock split. However, the Company must receive consents from the holders of a majority of the outstanding shares to proceed with the planned reverse stock split. Accordingly, th
Apr 13, 2023 08:04 am ET
First Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical Trial with RGN-259
ROCKVILLE, Md., April 13, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair, and regeneration, has announced that on April 12, the first patient of the Phase 3 clinical trial (SEER-2) of RGN-259, a novel treatment for neurotrophic keratitis (NK), has been enrolled and begun treatment.  The product candidate is under development by ReGenTree, LLC, a U.S. joint venture between RegeneRx and HLB Therapeutics.
Apr 11, 2023 04:59 pm ET
RegeneRx Issues Letter To Stockholders
ROCKVILLE, Md., April 11, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair, and regeneration, has issued a Letter to Stockholders updating its ongoing operating strategy.  The Letter may be viewed at RegeneRx's homepage: www.regenerx.com.
Jan 31, 2023 07:30 am ET
Thymosin Beta 4 Research Leads Toward Potential Future Anti-aging Therapy
ROCKVILLE, Md., Jan. 31, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair, and regeneration, is reporting today a new scientific publication describing Thymosin beta 4's (Tβ4) potential as an anti-aging therapy.
Jan 03, 2023 07:14 am ET
Publication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic Keratopathy
ROCKVILLE, Md., Jan. 3, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair, and regeneration, is reporting today a new scientific publication describing the safety and efficacy of RGN-259 eyedrops in a phase 3 clinical trial in patients with Neurotrophic Keratopathy (NK). The product candidate is being developed by ReGenTree, LLC, a U.S. joint venture between RegeneRx Biopharmaceuticals and HLB Therapeutics.
Oct 24, 2022 10:55 am ET
RegeneRx Licensee Submits Special Protocol Assessment to FDA for 4th Phase 3 Clinical Trial for Dry Eye Disease
Expect ARISE-4 Trial to Begin Around 2nd Quarter of 2023
Sep 27, 2022 12:24 pm ET
RegeneRx Partner Submits Phase 3 Protocol for Neurotrophic Keratopathy (NK)
First of Two Phase 3 NK Trials Expected to Start in November 2022
Aug 22, 2022 08:30 am ET
RegeneRx Issues 2022 Letter To Stockholders
Update on Product Candidates, FDA Regulatory Strategy, Operations
Jul 18, 2022 08:30 am ET
RegeneRx Partner Signs LOI with Global Ophthalmology CRO for Two Phase 3 Clinical Trials in Neurotrophic Keratitis
ROCKVILLE, Md., July 18, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair, and regeneration, is reporting today that its U.S. joint venture (JV) partner and licensee, HLB Therapeutics (HLBT), has signed a letter of intent with a global ophthalmology contract research organization (CRO) to conduct two phase 3 clinical trials simultaneously beginning in the Fall 2022 in the U.S. and Europe for patients with neurotrophic keratitis (NK).
Jun 22, 2022 08:30 am ET
RegeneRx Licensee to Expand Phase 3 Clinical Trial Program with RGN-259
ROCKVILLE, Md., June 22, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair, and regeneration, is reporting today that its U.S. joint venture (JV) partner and licensee, HLB Therapeutics (HLBT), is planning to expand its ophthalmic clinical development program with RGN-259 in two indications, Neurotrophic Keratopathy (NK) and Dry Eye Disease (DED), beginning in November of 2022.  The trials will be sponsored by the U.S. JV, ReGenTree, LLC.
May 04, 2022 10:29 am ET
Tβ4 Shows Potential as a Combination Treatment for Diabetes-Induced Complications of the Cornea
ROCKVILLE, Md., May 4, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair, and regeneration, is reporting that researchers have demonstrated the therapeutic efficacy of Thymosin Beta 4 (Tβ4) as a combination treatment against hyperglycemia (diabetic)-induced changes in human corneal epithelial cells.
Mar 02, 2022 07:30 am ET
RegeneRx Provides Regulatory Update Regarding RGN-259
ROCKVILLE, Md., March 2, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration has posted information released by HLB Therapeutics in Korea pursuant to the pre-BLA meeting with the FDA on February 28, 2022. HLB recently acquired GtreeBNT and is RegeneRx's U.S. joint venture partner developing RGN-259 for the treatment of ophthalmic injuries and disorders, including dry eye syndrome and neurotrophic keratitis.
Feb 11, 2022 07:23 am ET
RegeneRx Consultant to Receive Prestigious Award for Contributions in Field of Health
ROCKVILLE, Md., Feb. 11, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair, and regeneration, today announced that Dr. Hynda K. Kleinman, a consultant to the Company, will receive the Second Biennial Dr. Gertrude Herzfeld International Jewish Woman of the Year Prize for Health. Dr. Kleinman will be the first living Jewish female in the world to receive the prestigious Herzfeld Prize. Her career and personal life emulate and mirror the historic achievements of Dr. Herzfeld both in h
Jan 12, 2022 08:30 am ET
RegeneRx Publishes Regulatory Update on RGN-259
ROCKVILLE, Md., Jan. 12, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today published an update regarding the regulatory progress of RGN-259 on the Company's website at www.regenerx.com.
Dec 17, 2021 08:43 am ET
RegeneRx Joint Venture Will Hold Pre-BLA Meeting with FDA on February 28, 2022
ROCKVILLE, Md., Dec. 17, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that the U.S. FDA has accepted its request for a pre-BLA meeting pursuant to RGN-259, its novel product candidate for dry eye syndrome. The meeting is scheduled for February 28, 2022. A BLA (Biologics License Application) is FDA's standard "full approval" mechanism for biological products, including therapeutics and vaccines.
Nov 29, 2021 07:30 am ET
RegeneRx Joint Venture Requests Pre-BLA Meeting with FDA For RGN-259 for Dry Eye Syndrome
ROCKVILLE, Md., Nov. 29, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration), today announced that its U.S. joint venture, ReGenTree LLC, has submitted a letter to the U.S. FDA requesting a pre-BLA meeting pursuant to RGN-259, its novel product candidate for dry eye syndrome. A BLA (Biologics License Application) is FDA's standard "full approval" mechanism for biological products, including therapeutics and vaccines.
Oct 29, 2021 11:08 am ET
Clinical Results of RGN-259 for the Treatment of Neurotrophic Keratitis to be Presented at 2021 American Ophthalmology Association Meeting
ROCKVILLE, Md., Oct. 29, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration), today announced that the results of the initial randomized, double-masked, placebo-controlled, phase 3 clinical trial of RGN-259 for the treatment of neurotrophic keratitis (SEER-1) will be presented at the 2021 American Ophthalmology Association meeting in New Orleans, LA on November 12-15.  The results will be jointly presented by ReGenTree LLC, the Company's U.S. joint venture to develo
Oct 06, 2021 09:20 am ET
Researchers Identify Thymosin Beta 4's Potential Role in Treatment of Acute Kidney Injury and the Reduction of Mortality in Patients with Sepsis
ROCKVILLE, Md., Oct. 6, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration), today announced that a new independent research paper was published identifying Thymosin Beta 4's (Tβ4) potential in the diagnosis and treatment of acute kidney injury and reduction of mortality in patients with sepsis.
Oct 05, 2021 08:30 am ET
New Research Demonstrates Thymosin Beta 4's Potential Positive Effects on Alzheimer's Disease
ROCKVILLE, Md., Oct. 5, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration), today announced that a new research paper was published demonstrating Thymosin Beta 4's (Tβ4) positive effects on animal models related to Alzheimer's Disease.
Sep 27, 2021 08:30 am ET
RegeneRx Licensee Acquired by Korean Biopharmaceutical Group
ROCKVILLE, Md., Sept. 27, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration), today announced that GtreeBNT, the licensee for several RegeneRx products, is being acquired by HLB Group, a Korean company that includes six biopharmaceutical and financial subsidiaries in Korea and the U.S. 
Jul 22, 2021 08:30 am ET
RegeneRx Issues Letter To Stockholders
ROCKVILLE, Md., July 22, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, has issued a Letter to Stockholders updating its recent financing, the FDA regulatory process for RGN-259, and its 12-month operating strategy.  The Letter may be viewed at RegeneRx's homepage: www.regenerx.com.
Jul 14, 2021 08:07 am ET
RegeneRx JV Updates RGN-259 Regulatory Progress for Dry Eye Syndrome
ROCKVILLE, Md., July 14, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration has released an update from its U.S. joint venture, ReGenTree LLC, regarding its progress and prospects of a pre-BLA (Biologics License Application) meeting with FDA. 
Jul 01, 2021 01:00 pm ET
RegeneRx Biopharmaceuticals, Inc. Closes $2 Million Private Placement
ROCKVILLE, Md., July 1, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration), today announced that it closed its previously announced private placement offering of common stock and warrants for gross proceeds of $1,980,000.  RegeneRx will be issuing to purchasers of common stock Series A Warrants to purchase up to approximately 7.5 million shares of common stock with an exercise price of $0.24 per share, exercisable immediately and have a term of two years following
Jun 28, 2021 04:15 pm ET
RegeneRx Biopharmaceuticals, Inc. Announces $2 Million Private Placement
ROCKVILLE, Md., June 28, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration), today announced that it has entered into a definitive agreement with certain institutional and accredited investors, including certain directors and officers of the Company, in connection with a private placement of up to $2,000,000 of shares of its common stock and warrants at a purchase price of $0.20 per share and accompanying warrants. RegeneRx will be issuing to each purchaser Series
Feb 24, 2021 07:22 am ET
RegeneRx JV Locks Clinical Trial Database for Phase 3 Dry Eye Trial
ROCKVILLE, Md., Feb. 24, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage biopharmaceutical company focused on tissue protection, repair and regeneration, announced that the ARISE-3 Phase 3 clinical trial database evaluating RGN-259 eyedrops for the treatment of dry eye syndrome has been locked after collecting and verifying patient data from 20 U.S. clinical sites participating in the study.  Database lock is a specific time point prior to unmasking the trial and after which no patient information may be modified.
Jan 26, 2021 09:46 am ET
RegeneRx Comments on ARISE-3 Clinical Trial
ROCKVILLE, Md., Jan. 26, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, is addressing rumors in the market regarding its ARISE-3 phase 3 dry eye trial. 
Dec 21, 2020 08:25 am ET
RegeneRx Issues Year End Letter To Stockholders
ROCKVILLE, Md., Dec. 21, 2020 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, issued a year-end Letter to Stockholders.  The Letter may be viewed at RegeneRx's homepage: www.regenerx.com.
Nov 09, 2020 08:28 am ET
Last Patient, Last Visit Completed in RegeneRx Phase 3 Dry Eye Clinical Trial
ROCKVILLE, Md., Nov. 9, 2020 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration announced today that the final patient in its 700 subject, ARISE-3 phase 3 clinical trial for dry eye syndrome has completed treatment and follow-up.  The ARISE-3 trial is being sponsored by ReGenTree, LLC, a U.S. joint venture company owned by RegeneRx and G-treeBNT, a Korean biopharmaceutical company.
Oct 28, 2020 08:30 am ET
RegeneRx Joint Venture Enrolls Last Subject in Phase 3 Dry Eye Trial
ROCKVILLE, Md., Oct. 28, 2020 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration announced today that its joint venture, ReGenTree LLC, has enrolled the last of 700 subjects in the ARISE-3 phase 3 clinical trial for dry eye syndrome.  Completion of treatment and follow-up for the last subject is anticipated to be by the end of November 2020.  ReGenTree is a U.S. joint venture company owned by RegeneRx and GtreeBNT, a Korean biopharmaceutical company.
Oct 21, 2020 11:20 am ET
RegeneRx Closes Convertible Debt Financing
ROCKVILLE, Md., Oct. 21, 2020 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has completed a $500,000 convertible debt financing.  The funds will be used for operations while awaiting completion of its phase 3 dry eye clinical trial (ARISE-3) in December and sponsored by its U.S. joint venture, ReGenTree, LLC.
Oct 14, 2020 10:32 am ET
ARISE-3 Phase 3 Trial Completion Expected by End of 2020
ROCKVILLE, Md., Oct. 14, 2020 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration announced today that enrollment in the 700-patient, phase 3 clinical trial for dry eye syndrome (ARISE-3) is expected to be completed in November, 2020, and that the estimated study completion date and collection of data for the primary and secondary outcome measures will be in December, 2020.  Additional information may be found on www.clinicaltrials.gov.
Jun 02, 2020 09:17 am ET
RegeneRx Advisory on ARISE-3 Dry Eye Trial
ROCKVILLE, Md., June 2, 2020 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration has posted information on its website regarding the revised schedule for completion of the ARISE-3 dry eye clinical trial, http://www.regenerx.com/2020-06-02-June-2-2020-Advisory-Update-on-ARISE-3-Dry-Eye-Trial.
May 27, 2020 11:33 am ET
RegeneRx Advisory on Reclassification of Thymosin Beta 4 from Drug to Biologic
ROCKVILLE, Md., May 27, 2020 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration has posted information on its website regarding the FDA's reclassification of Thymosin beta 4 (Tβ4) from a drug to a biologic, http://www.regenerx.com/2020-05-27-Reclassification-of-Thymosin-Beta-4-from-New-Drug-Entity-to-Biologic.
May 14, 2020 05:30 am ET
RegeneRx Joint Venture Announces Efficacy Results of Neurotrophic Keratopathy Phase 3 Clinical Trial with RGN-259
ROCKVILLE, Md., May 14, 2020 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration announced efficacy results of its Phase 3 clinical trial in patients with neurotrophic keratopathy (NK). The full text of the press release, released through its U.S. joint venture, ReGenTree LLC., is included below:
Apr 20, 2020 08:18 am ET
RegeneRx Issues Advisory on ARISE-3 Dry Eye Trial
ROCKVILLE, Md., April 20, 2020 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration issued an advisory on its dry eye syndrome Phase 3 clinical trial.  To access the advisory, go to the following link:  http://www.regenerx.com/2020-04-20-April-20-2020-Advisory-Update-on-ARISE-3-Dry-Eye-Trial.  
Apr 02, 2020 12:38 pm ET
New Publication Describes Mechanism of Action for Tβ4 in Corneal Wound Healing and Regeneration
ROCKVILLE, Md., April 2, 2020 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or the "Company"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced the publication of a new scientific study demonstrating a mechanism of action of thymosin beta 4 (Tβ4) on human corneal epithelial cell migration and the downstream signaling pathways. Although Tβ4 is in phase 3 clinical trials for treatment of eye disorders such as dry eye syndrome and neurotrophic keratitis, the effect of Tβ4 on human corneal epithel
Mar 18, 2020 08:34 am ET
RegeneRx Issues Advisory on Dry Eye Trial Amid COVID-19 Virus
ROCKVILLE, Md., March 18, 2020 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration issued an advisory on its dry eye syndrome Phase 3 clinical trial.  To access the advisory, go to the following link:  http://www.regenerx.com/2020-03-18-March-18-2020-Advisory-Update-on-Phase-3-Dry-Eye-Trial-Amid-COVID-19-Virus.
Nov 14, 2019 07:30 am ET
RegeneRx's Tβ4 Promotes Autophagy and Repair in Chronic Granulomatous Disease Model
ROCKVILLE, Md., Nov. 14, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or the "Company"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced the publication of a new scientific study demonstrating how Thymosin beta 4 (Tβ4) promotes the body's ability to clean out damaged cells in order to regenerate newer, healthier cells (autophagy) and repair damage in chronic granulomatous disease (CGD).  
Oct 16, 2019 08:17 am ET
RegeneRx JV Partner Updates on Strategic Dry Eye Discussions
ROCKVILLE, Md., Oct. 16, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, released a summary of its U.S. joint venture partner, GtreeBNT's, recent attendance at the American Academy of Ophthalmology meeting (AAO) in San Francisco, California. The following summary was provided to RegeneRx by GtreeBNT and is posted on Gtree's web site:
Sep 30, 2019 09:34 am ET
RegeneRx Partner Updates on ARISE-3 Clinical Trial
ROCKVILLE, Md., Sept. 30, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, announced today that GtreeBNT, its Korean partner in the U.S. development of RGN-259 for the treatment of dry eye disease, issued an update on the U.S. phase 3 clinical trial.  The following translation was provided to RegeneRx by GtreeBNT, with certain clarifications made by RegeneRx:
Sep 10, 2019 08:30 am ET
RegeneRx to Present at Fall Investor Summit on September 17
ROCKVILLE, Md., Sept. 10, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that J.J. Finkelstein, President and Chief Executive Officer, will present a corporate update at the Fall Investor Summit on September 17, 2019, at 8:30 a.m. ET in New York City.  The presentation will be webcast and can be accessed by the following link:  https://www.webcaster4.com/Webcast/Page/2038/31564.  A slide presentation will also be available on th
Sep 04, 2019 09:14 am ET
RegeneRx Modifies September Conference Schedule
ROCKVILLE, Md., Sept. 4, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that J.J. Finkelstein, President and Chief Executive Officer, will present a corporate update at The Fall Investor Summit on September 16-17, 2019, in New York City.  The specific presentation date, time and webcast information will be announced as soon as determined by the conference schedulers.  The Company will not be presenting at the Rodman & Rensha
Aug 05, 2019 02:00 pm ET
First Patient Enrolled in RGN-137 Trial for Epidermolysis Bullosa Experiences Complete Wound Healing
ROCKVILLE, Md., Aug. 5, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today confirmed that the first patient enrolled in a single-blinded, phase 2 clinical trial in patients with epidermolysis bullosa (EB) has positively responded to RGN-137, the Company's novel topically-administered drug candidate.
Jul 29, 2019 01:16 pm ET
RegeneRx's RGN-137 for Epidermolysis Bullosa Subject of New Article in Seeking Alpha Investor Site
ROCKVILLE, Md., July 29, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that RGN-137, the Company's wound healing product candidate currently the subject of a U.S. clinical trial, is the subject of an in depth article in Seeking Alpha, a financial website producing original reports and research covering a broad range of stocks, asset classes, ETFs and investment strategies.  The article describes the current clinical status of R
Jul 16, 2019 09:43 am ET
RegeneRx to Present at the Rodman & Renshaw and the Fall Investor Summit Conferences in September 2019
ROCKVILLE, Md., July 16, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that J.J. Finkelstein, President and Chief Executive Officer, will present a corporate update at the Rodman & Renshaw 21st Annual Global Investment Conference on September 8-10, 2019 and the Fall Investor Summit on September 16-17, 2019, both in New York City.  Specific presentation dates, times and webcast information will be announced in August.
May 16, 2019 12:19 pm ET
RegeneRx Partner Receives Patent for New Ophthalmic Formulation of Thymosin Beta 4
ROCKVILLE, Md., May 16, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, reported today that its U.S. joint venture partner and Pan Asian licensee, GtreeBNT, has been granted a new U.S. patent for a method of preventing or treating dry eye syndrome by administering Tβ4 with non-active ingredients to provide improved pharmacodynamics.  Tβ4 is the active component of RGN-259, currently in separate phase 3 clinical trials for dry eye syndrome and ne
May 13, 2019 09:47 am ET
First Patient Enrolled in RegeneRx JV Phase 3 Dry Eye Trial
ROCKVILLE, Md., May 13, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, announced today that the first patient has been enrolled in ARISE-3, a phase 3 clinical trial sponsored by ReGenTree LLC, a U.S. joint venture between RegeneRx and GtreeBNT, a Korean biopharmaceutical company.  The clinical trial will evaluate RGN-259, a sterile, preservative-free eye drop in 700 patients with dry eye syndrome (DES) at approximately fifteen nationwide clinic
Apr 22, 2019 11:26 am ET
RegeneRx Publishes Annual Letter to Shareholders
ROCKVILLE, Md., April 22, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today published its annual letter to stockholders on the Company's website at www.regenerx.com.
Mar 27, 2019 09:16 am ET
RegeneRx to Present at 2019 Spring Investor Summit
ROCKVILLE, Md., March 27, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that J.J. Finkelstein, President and Chief Executive Officer, will present a corporate update at the Spring Investor Summit taking place on April 1-2, 2019 in New York, NY.  Mr. Finkelstein will speak on Tuesday, April 2 at 9:00 a.m. ET.  A copy of his presentation will be available on the Company's website at http://www.regenerx.com/presentations on Tuesda
Mar 26, 2019 09:13 am ET
RegeneRx and Lee's Pharm to Accelerate RGN-259 Development in China
ROCKVILLE, Md. and HONG KONG, March 26, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, and Lee's Pharmaceutical Holdings Limited ("Lee's Pharm"), a Hong Kong-based pharmaceutical company, are accelerating development of RGN-259 in China for ophthalmic indications.  Lee's Pharm previously licensed RGN-259, RegeneRx's sterile, preservative-free, topical eye drop developed for the treatment of ophthalmic indications such as dry eye syndrome (DES),
Mar 21, 2019 08:30 am ET
RegeneRx Announces New Board Member
ROCKVILLE, Md., March 21, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced the appointment of Alessandro Noseda M.D. to the Company's Board of Directors, effective April 1, 2019.  He will be the sixth member of the Company's Board.
Feb 27, 2019 01:11 pm ET
RegeneRx Closes $1.3 Million Convertible Debt Financing
ROCKVILLE, Md., Feb. 27, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has completed a $1.3 million convertible debt financing.  The funds will be used for operations over the next approximately 12 months while a phase 3 dry eye trial (ARISE-3), phase 3 neurotrophic keratitis trial (SEER-1), and epidermolysis bullosa open study are being conducted by its partner and licensee.
Feb 12, 2019 06:38 am ET
RegeneRx's U.S. Joint Venture Initiates Key Phase 3 Dry Eye Clinical Trial with RGN-259
ROCKVILLE, Md., Feb. 12, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, announced today that ReGenTree, LLC, a joint venture between GtreeBNT and RegeneRx, has executed an agreement with Ora, Inc., located in Andover, Massachusetts, for initiation of ARISE-3 to study ReGenTree's new drug, RGN-259, a sterile, preservative-free eye drop for the treatment of dry eye syndrome. ARISE-3 is a randomized double-masked, placebo-controlled phase 3 clinic
Jan 04, 2019 10:00 am ET
RegeneRx Update on Dry Eye and EB Clinical Trials
ROCKVILLE, Md., Jan. 4, 2019 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, is updating the status of the U.S. phase 3 dry eye clinical trial (ARISE-3) and the U.S. trial in patients with epidermolysis bullosa (EB) based on a letter to stockholders issued today by its partner, GtreeBNT.  GtreeBNT is the sponsor of the EB trial while a U.S. joint venture between GtreeBNT and RegeneRx, ReGenTree, LLC, is the sponsor of the dry eye trial. 
Oct 29, 2018 10:16 am ET
RegeneRx Partner Updates on Clinical Trials
ROCKVILLE, Md., Oct. 29, 2018 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced a clinical trial update provided by GtreeBNT, RegeneRx's partner for development of RGN-259 and RGN-137 in the U.S.:
Sep 06, 2018 07:33 am ET
World Health Organization Recommends INN for Thymosin Beta 4 as "timbetasin"
ROCKVILLE, Md., Sept. 6, 2018 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that the recommended INN (International Nonproprietary Name) for Thymosin Beta 4 is timbetasin, as published by the World Health Organization (WHO).
Aug 02, 2018 08:30 am ET
RegeneRx Licensee GtreeBNT Enters into Joint Venture to Globally Develop RGN-137 for Treatment of Epidermolysis Bullosa
ROCKVILLE, Md., Aug. 2, 2018 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its licensee for RGN-137, GtreeBNT, has entered into a joint venture with YuYang DNU, a Korean company, to develop RGN-137 on a global basis for the orphan indication, epidermolysis bullosa (EB).  The joint venture between the two companies is Lenus Therapeutics, LLC (Lenus), a GtreeBNT U.S. subsidiary.  Gtree will contribute the intellectual property ri
Jul 16, 2018 09:25 am ET
RGN-259 (Tβ4) Improves Clinically Important Dry Eye Efficacies in Comparison with Prescription Drugs in Dry Eye Model
ROCKVILLE, Md., July 16, 2018 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that a new study was published comparing RGN-259 with currently approved prescription products for dry eye syndrome (DES).  In the study, researchers demonstrated that after ten days of treatment RGN-259 performed equal to or better than cyclosporine A (Restasis®), lifitegrast (Xiidra®), and diquafosol (Diquas®).  The study parameters measured were tear prod
Jun 13, 2018 01:13 pm ET
RegeneRx Holds Annual Meeting
ROCKVILLE, Md., June 13, 2018 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), today held its 2018 Annual Meeting.  Seventy-eight of the Company's stockholders voted on four proposals.  Each proposal was approved by a minimum of 92% of the voting stockholders.
May 29, 2018 10:57 am ET
RegeneRx Corrects Annual Meeting Date to Wednesday, June 13, 2018
ROCKVILLE, Md., May 29, 2018 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), today is correcting a misprinted annual meeting date in the Company's proxy materials that were sent to its stockholders on May 15, 2018 (the "Meeting Notice").  The Meeting Notice mistakenly indicated that the Annual Meeting would be held on Tuesday, June 13.  The Annual Meeting will be held on Wednesday, June 13, 2018 at 11:00 a.m. ET as the Company's offices. 
May 02, 2018 08:30 am ET
ReGenTree Presents Results of a Comparison Study of RGN-259 and Approved Prescription Drugs for Dry Eye Syndrome in a Mouse Model at ARVO
ROCKVILLE, Md., May 2, 2018 /PRNewswire/ -- ReGenTree, LLC (the "Company"), a joint venture between GtreeBNT and RegeneRx Biopharmaceuticals (OTCQB: RGRX), announced today that the Company presented results of a comparison study of RGN-259 and marketed products for dry eye syndrome in a dry eye mouse model at ARVO (The Association for Research in Vision and Ophthalmology) meeting in Honolulu, Hawaii. The study was conducted by Jaewook Yang, M.D. at the T2B Infrastructure Center for Ocular Disease, InJe University Busan Paik Hospital in Korea. Gabriel Sosne, M.D. at Wayne State University Sch
Apr 25, 2018 08:30 am ET
GtreeBNT Discloses Preliminary Observations from Seventeen NK Patients Treated with RGN-259 Eye Drops
ROCKVILLE, Md., April 25, 2018 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today is informing stockholders that GtreeBNT, its joint venture partner for development of RGN-259 in the U.S., has disclosed that 7 of 17 patients enrolled in an orphan Phase 3 clinical trial for neurotrophic keratopathy (NK) have completely healed.  To participate in the trial the patients must have a persistent epithelial defect (non-healing corneal wound).  While thes
Apr 09, 2018 07:05 am ET
RegeneRx Announces Outcome of FDA Discussions for Development of RGN-259 for Dry Eye Syndrome
ROCKVILLE, Md., April 9, 2018 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced the outcome of discussions between its U.S. joint venture, ReGenTree LLC, and the FDA regarding the results of the completed phase 3 clinical trial (ARISE-2) and the future development requirements for a New Drug Application ("NDA") submission of RGN-259, a novel drug candidate to treat dry eye syndrome.
Mar 14, 2018 09:17 am ET
RegeneRx Receives Notice of Allowance of U.S. Patent for Treatment of Corneal Wounds
ROCKVILLE, Md., March 14, 2018 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a new patent for treating corneal wounds using Thymosin beta 4 (Tβ4) or related therapeutic peptides.  Tβ4 is the active pharmaceutical ingredient in RegeneRx's proprietary drug candidate, RGN-259, a first-in-class, preservative-free, eye drop designed for patients suffer
Mar 12, 2018 08:30 am ET
RegeneRx Receives "Decision to Grant" European Patent For Treatment of Peripheral Neuropathy
ROCKVILLE, Md., March 12, 2018 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that the European Patent Office has issued a Decision to Grant a new patent for treating patients with peripheral neuropathy using Thymosin beta 4 (Tβ4).  Tβ4 is the active pharmaceutical ingredient in RegeneRx's proprietary drug candidate, RGN-352, a first-in-class injectable formulation designed for systemic administration.   
Mar 02, 2018 10:32 am ET
RegeneRx Secures $1 Million in Funding
ROCKVILLE, Md., March 2, 2018 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it entered into a Warrant Reprice Agreement whereby it received $1.03 million in warrant exercise proceeds. This is in connection with a previous securities purchase agreement between the Company and Sabby Healthcare Master Fund, Ltd., and Sabby Volatility Warrant Master Fund, Ltd.  dated June 27, 2016 whereby the Company also issued warrants to purchas
Feb 22, 2018 06:54 am ET
Key U.S. Dry Eye Patent Issued to RegeneRx
ROCKVILLE, Md., Feb. 22, 2018 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX)("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent for Thymosin beta 4 (Tβ4) for use in the treatment of dry eye syndrome.  Tβ4 is the active pharmaceutical ingredient in RegeneRx's proprietary drug candidate, RGN-259, a first-in-class, preservative-free, eye drop designed for patients suffering from moderate to severe dry eye syndrome. 
Feb 14, 2018 08:25 am ET
RegeneRx Receives Canadian Patent for Treating Neurological Injury and Damage
ROCKVILLE, Md., Feb. 14, 2018 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that the Canadian Patent Office has issued a Notice of Allowance for Thymosin beta 4 (Tβ4) for use in the treatment of neurological injury and damage.  Tβ4 is the active pharmaceutical ingredient in RegeneRx's proprietary drug candidate, RGN-352, a first-in-class product candidate designed for systemic administration to patients suffering from neurological i
Dec 07, 2017 01:33 pm ET
RegeneRx Releases Annual Letter to Shareholders
ROCKVILLE, Md., Dec. 7, 2017 /PRNewswire/ --RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its year end letter to shareholders. The letter is focused on updating shareholders on the Company's product development and commercial partnerships, clinical trials, fund-raising, and other operational plans over the next twelve months. To view the letter, please go to www.regenerx.com.
Nov 16, 2017 08:31 am ET
Tβ4's Role in Treatment of Eye Diseases Showcased at 5th International Thymosin Symposium
ROCKVILLE, Md., Nov. 16, 2017 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that Thymosin beta 4 (Tβ4), the active ingredient in RGN-259, a preservative-free ophthalmic eye drop, was the subject of a Keynote Address at the 5th International Symposium of Thymosins in Health and Disease in Washington, DC.
Oct 31, 2017 09:00 am ET
RegeneRx JV Announces Results of ARISE-2 Dry Eye Trial
ROCKVILLE, Md., Oct. 31, 2017 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced the results of its phase 3 dry eye trial sponsored by its U.S. joint venture, ReGenTree, LLC.  The ARISE-2 trial investigated the safety and efficacy of RGN-259 compared to placebo for the treatment of the signs and symptoms of dry eye syndrome in 601 patients. 
Sep 13, 2017 11:09 am ET
RegeneRx Receives Notice of Allowance for Key Dry Eye Patent in U.S.
ROCKVILLE, Md., Sept. 13, 2017 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Thymosin beta 4 (Tβ4) for use in the treatment of dry eye syndrome.  Tβ4 is the active pharmaceutical ingredient in RegeneRx's proprietary drug candidate, RGN-259, a first-in-class product candidate designed for topical administration to patients suffering from dry eye sy
Aug 31, 2017 09:57 am ET
RegeneRx Completes License Expansion for RGN-137 in Europe, S. Korea, Japan, Canada and Australia
ROCKVILLE, Md., Aug. 31, 2017 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has completed a license expansion agreement with GtreeBNT for the rights to RGN-137, RegeneRx's topical gel formulation of thymosin beta 4 (Tβ4), in Europe, S. Korea,  Japan, Canada and Australia.
Aug 30, 2017 12:12 pm ET
RegeneRx Announces Participation At The 19th Annual Rodman & Renshaw Global Investment Conference In New York September 10-12, 2017
ROCKVILLE, Md., Aug. 30, 2017 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced it will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC.  The conference is being held on September 10-12, 2017 at Lotte New York Palace Hotel in New York City.
Aug 14, 2017 10:21 am ET
RegeneRx Collaborators Receive Notice of 'Intent to Grant' EU Patent for the Treatment of Peripheral Neuropathy
ROCKVILLE, Md., Aug. 14, 2017 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that the European Patent Office (EPO) has issued an Intent to Grant notice related to Thymosin beta 4 (Tβ4) for use in the treatment of peripheral neuropathy.  Tβ4 is the active pharmaceutical ingredient in RegeneRx's proprietary drug candidate, RGN-352, a first-in-class product candidate designed for systemic administration to treat damaged tissue. 
Jul 27, 2017 11:51 am ET
RegeneRx Updates on RGN-259 Phase 3 Dry Eye Trial
ROCKVILLE, Md., July 27, 2017 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its U.S. joint venture, ReGenTree LLC, has completed treatment of the last patient enrolled in its Phase 3 "ARISE-2" clinical trial testing RGN-259 preservative-free eye drops for dry eye syndrome ("DES").
Jun 13, 2017 09:30 am ET
RegeneRx Collaborators Receive Notice of Allowance of U.S. Patent for the Treatment of Peripheral Neuropathy
ROCKVILLE, Md., June 13, 2017 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that a Notice of Allowance has been received from the U.S. Patent and Trademark Office (USPTO) related to the composition and use of Thymosin beta 4 (Tβ4) and certain of its peptide constituents.  Tβ4 is the active pharmaceutical ingredient in RegeneRx's proprietary drug candidate, RGN-352, a first-in-class product candidate for the treatment
May 09, 2017 11:00 am ET
RegeneRx JV Presents Results of Phase 2b/3 (ARISE-1) Dry Eye Trial at ARVO 2017
ROCKVILLE, Md., May 9, 2017 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, announced that its joint venture, ReGenTree LLC, presented the results of its ARISE-1 Phase 2b/3 dry eye clinical trial in a poster session to physicians, scientists, and analysts today at the 2017 ARVO meeting in Baltimore, Maryland.    
Mar 13, 2017 09:30 am ET
RegeneRx Releases Annual Letter to Shareholders
ROCKVILLE, Md., March 13, 2017 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has released its annual letter to shareholders. The 2017 letter is focused on updating shareholders on the Company's product development and commercial partnerships, anticipated clinical milestones, fund-raising, and other operational plans over the next twelve months. To view the letter, please go to www.regenerx.com or click on the following link:
Feb 27, 2017 08:30 am ET
RegeneRx Licensee Receives FDA Permission to Conduct a Phase 3 Trial of RGN-137 for Epidermolysis Bullosa in U.S.
ROCKVILLE, Md., Feb. 27, 2017 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its licensee for RGN-137, GtreeBNT Co., Ltd., received a positive response from the U.S. FDA for its Phase 3 clinical trial design for RGN-137 to treat epidermolysis bullosa ("EB"). RGN-137 is a dermal wound healing gel that incorporates Thymosin beta 4 ("Tβ4") as the active pharmaceutical ingredient. GtreeBNT is planning to enter into the Phase 3 trial
Jan 09, 2017 08:30 am ET
RegeneRx Receives Notice of Acceptance for Patent in Australia For Treatment of Neural Injury with Thymosin Beta 4.
ROCKVILLE, Md., Jan. 9, 2017 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has received a Notice of Acceptance for a patent from the Australian Patent Office for the use of Thymosin beta 4 (Tβ4), the active pharmaceutical ingredient in the RegeneRx's proprietary drug candidate, RGN-352, to myelinate damaged neurons or axons (brain nerve cells). Myelination is a process of forming a myelin sheath around a nerve to allow nerve
Dec 16, 2016 09:35 am ET
RegeneRx Receives Notice of Intent to Grant Patent in EU for Treating Neural Injury with Thymosin Beta 4
ROCKVILLE, Md., Dec. 16, 2016 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has received notice of Intent to Grant a patent from the European Patent Office for treating neural injury using Thymosin beta 4 (Tβ4), the active pharmaceutical ingredient in the RegeneRx's proprietary drug candidate, RGN-352. The treatment claims include treating neural injury by remyelinating damaged neurons using Tβ4, which has been shown to prom
Nov 30, 2016 08:30 am ET
RegeneRx to Present at 9th Annual LD Micro Investor Conference
ROCKVILLE, Md., Nov. 30, 2016 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that J.J. Finkelstein, President and Chief Executive Officer, will present a corporate overview at the 9th Annual LD Micro Investor Conference taking place on December 6-8, 2016 in Los Angeles, CA. 
Nov 09, 2016 08:26 am ET
RegeneRx Announces First Patients Enrolled in Phase 3 U.S. Dry Eye Clinical Trial (ARISE-2 Trial) with RGN-259
ROCKVILLE, Md., Nov. 9, 2016 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, announced today that the first patients have been enrolled in a Phase 3 clinical trial (ARISE-2 trial) with RGN-259 (Thymosin beta 4), its sterile, preservative-free eye drop formulation developed for patients with dry eye syndrome, neurotrophic keratopathy (NK), and other corneal disorders.
Nov 02, 2016 12:50 pm ET
RegeneRx Receives Notice of Allowance for Patent for Tβ4 Eye Drop Formulation
ROCKVILLE, Md., Nov. 2, 2016 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a single unit dosage eye drop formulation containing Thymosin beta 4 (Tβ4). Tβ4 is the active pharmaceutical ingredient in RGN-259, RegeneRx's preservative-free eye drops currently in Phase 3 clinical trials. 
Sep 30, 2016 11:20 am ET
RegeneRx Joint Venture Initiates Second Phase 3 Study Of RGN-259 for Dry Eye Syndrome
ROCKVILLE, Md., Sept. 30, 2016 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, announced today that ReGenTree, RegeneRx's U.S. joint venture with GtreeBNT, initiated its second Phase 3 trial for Dry Eye Syndrome this month and will begin patient enrollment shortly. The double-masked, placebo-controlled trial is expected to enroll approximately 500 patients who will be treated for 28 days with RGN-259, the Company's proprietary, preservative-free eye
Aug 30, 2016 09:30 am ET
RegeneRx to Present at Rodman & Renshaw 18th Annual Global Investment Conference
ROCKVILLE, Md., Aug. 30, 2016 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that J.J. Finkelstein, President and Chief Executive Officer, will present a corporate overview at the Rodman & Renshaw 18th Annual Global Investment Conference taking place on September 11-13, 2016 at the Lotte New York Palace Hotel in New York City.  
Aug 29, 2016 09:30 am ET
RegeneRx Receives Notice of Intent to Grant Patent for the Treatment of Patients with Multiple Sclerosis in EU
ROCKVILLE, Md., Aug. 29, 2016 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has received notice of Intent to Grant a patent from the European Patent Office for the treatment of patients with MS. The patent covers use of the Company's proprietary molecule Thymosin beta 4 (Tβ4) in a composition for treating or reducing deterioration of, injury or damage to tissue due to MS. The patent expiry is January 13, 2026.
Aug 24, 2016 09:00 am ET
RegeneRx Joint Venture to Begin Second Phase 3 Study Of RGN-259 for Dry Eye Syndrome in 3rd Quarter
ROCKVILLE, Md., Aug. 24, 2016 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its U.S. joint venture, ReGenTree, LLC, has received permission from the U.S. FDA to proceed with a second Phase 3 clinical trial using RGN-259 to treat patients with dry eye syndrome (DES).
Aug 03, 2016 02:10 pm ET
RegeneRx Receives Notice of Allowance for Key U.S. Patent That Expands and Extends Exclusivity of Company's Product Candidates
ROCKVILLE, Md., Aug. 3, 2016 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a Method of Achieving a Thymosin Beta 4 Concentration in a Human Patient.  The patent covers treating a patient with a desired concentration of Thymosin Beta 4 (Tβ4) over a period of time, as well as treating a patient by maintaining a desired concentration of Tβ4
Jun 27, 2016 09:30 am ET
RegeneRx Announces $1.75 Million Private Placement
ROCKVILLE, Md., June 27, 2016 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has entered into a definitive agreement to sell 5,147,059 shares of common stock at a purchase price of $0.34 per share to a dedicated healthcare institutional investor in a private placement. In connection with the offering, the investor will also receive warrants to purchase up to 5,147,059 shares of common stock with an exercise price of $0.51 per
Jun 14, 2016 01:54 pm ET
Thymosin Beta 4 Effective in Treatment of Heart Attack Patients
ROCKVILLE, Md., June 14, 2016 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced a publication of a pilot clinical trial demonstrating that Thymosin beta 4 (Tβ4) was effective in the treatment of patients after an acute ST segment elevation myocardial infarction (STEMI), or heart attack
Jun 01, 2016 09:30 am ET
RegeneRx and Lee's Pharm Announce Acceleration of RGN-259 Development in China
ROCKVILLE, Md., June 1, 2016 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. ("RegeneRx", OTCQB: RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration, and Lee's Pharmaceutical Holdings Ltd., ("Lee's Pharm", HKEx Stock Code: 0950), a fully integrated bio-pharmaceutical company headquartered in Hong Kong, today announced acceleration of development of RGN-259 in China. According to Lee's Pharm, the Company's licensee and partner in China, in April the Chinese Food and Drug Administration (CFDA) modified its regulations for conducting clinical
May 27, 2016 12:47 pm ET
RegeneRx Comments on Valuation
ROCKVILLE, Md., May 27, 2016 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration, made the following comments today on its stock price:
May 17, 2016 09:59 am ET
RegeneRx Releases Letter to Stockholders
ROCKVILLE, Md., May 17, 2016 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today released the following letter to stockholders regarding its recent Phase 2/3 dry eye clinical trial:
May 10, 2016 12:21 pm ET
Rodman & Renshaw Updates Analyst Report on RegeneRx Biopharmaceuticals, Inc. with Buy Rating
ROCKVILLE, Md., May 10, 2016 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that Rodman & Renshaw, a unit of H.C. Wainwright & Co., has updated its analyst report on RegeneRx Biopharmaceuticals, Inc.  The firm has reiterated a Buy rating with a 12-month price target of $2 per share. The report is authored by Raghuram Selvaraju, Ph.D. and Yi Chen, Ph.D., CFA.  All recommendations and targets are based on the analysis of Rodman & Renshaw.
May 06, 2016 09:30 am ET
RGN-259 Confirms Efficacy in Signs and Symptoms of Dry Eye
ROCKVILLE, Md., May 6, 2016 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced positive results from its second clinical trial evaluating RGN-259 for the treatment of dry eye sponsored by ReGenTree LLC, its U.S. joint venture with GtreeBNT in Korea. The 317-patient Phase 2/3 trial (ClinicalTrials.gov Identifier: NCT02597803) demonstrated statistically significant improvements in both signs and symptoms of dry eye with 0.05% and 0.1% RGN-
Apr 28, 2016 09:30 am ET
RegeneRx and ReGenTree Expand License for Dry Eye
ROCKVILLE, Md., April 28, 2016 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx") today announced that it has expanded its license to ReGenTree, LLC for RGN-259 in North American from solely the U.S. to the U.S. and Canada.  The license expansion was negotiated pursuant to a term sheet that was previously announced by RegeneRx in its most recent Form 10-K.  RegeneRx previously received a payment from ReGenTree of $250,000 under the term sheet, which is the license fee for the expanded territory.  The U.S. license between the two companies has been a
Apr 06, 2016 12:12 pm ET
RegeneRx to Receive EU Patent for Use of Tβ4 in Preventing And Treating Damage Associated with Reperfusion Injury
ROCKVILLE, Md., April 6, 2016 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that the European Patent Office (EPO) has notified the Company that it intends to grant a patent covering the "Methods of Treating or Preventing Tissue Damage Caused by Increased Blood Flow."  The patent will cover protection, treatment, inhibition or reduction of damaged of tissue due to the increase of blood flow such as can occur when opening a blocked ar
Mar 14, 2016 10:20 am ET
Rodman & Renshaw Initiates Coverage of RegeneRx Biopharmaceuticals, Inc. with Buy Rating
ROCKVILLE, Md., March 14, 2016 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that Rodman & Renshaw, a unit of H.C. Wainwright & Co., has initiated coverage of RegeneRx Biopharmaceuticals, Inc.  The firm has issued a Buy rating with a 12-month price target of $2 per share. The report is authored by Raghuram Selvaraju, Ph.D. and Yi Chen, Ph.D., CFA and is available here: Click here for full report
Feb 01, 2016 08:30 am ET
RegeneRx Meeting with Institutional Investors and Analysts At BIO CEO Conference
ROCKVILLE, Md., Feb. 1, 2016 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or the "Company"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that J.J. Finkelstein, Chief Executive Officer, will be conducting one-on-one meetings with institutional investors and research analysts at the BIO CEO & Investor Conference in New York City. The conference will be held February 8-9, 2016 at The Waldorf Astoria Hotel.
Jan 29, 2016 08:32 am ET
RegeneRx Announces Completion of Patient Enrollment In Phase 2b/3 U.S. Dry Eye Trial
ROCKVILLE, Md., Jan. 29, 2016 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its U.S. joint venture with G-treeBNT, ReGenTree LLC, has completed enrollment of its Phase 2b/3 dry eye trial in the U.S.  The trial is testing RGN-259 (Thymosin beta 4), a sterile, preservative-free eye drop developed for patients with dry eye syndrome, neurotrophic keratopathy (NK), and other corneal disorders. 
Jan 28, 2016 08:30 am ET
RegeneRx U.S. Joint Venture, ReGenTree, Launches Web Site
ROCKVILLE, Md., Jan. 28, 2016 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its U.S. joint venture with G-treeBNT, ReGenTree LLC, has launched its website, www.regentreellc.com. The web site will be an access point for ReGenTree products and technologies and will include updates on clinical trials, regulatory and technology developments, and press releases.
Jan 27, 2016 08:30 am ET
RegeneRx's TB4 Shown to Promote Regeneration and Repair of Damaged Central Nervous System Cells
ROCKVILLE, Md, Jan. 27, 2016 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or the "Company"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced the publication of a new scientific study demonstrating how Thymosin beta 4 (Tβ4) initiates remyelination (restoration of the myelination sheath around nerve cells responsible for fast and accurate transmission of nerve signals) by promoting the differentiation of oligodendrocyte progenitor cells (OPCs) in two separate demyelination animal models, including t

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.

Learn More